Palbociclib 125mg Clinical Trials
6 recruitingDrug
Phase 13Phase 23Phase 31
Showing 1–6 of 6 trials
Recruiting
Phase 3
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Metastatic Breast Cancer
American Society of Clinical Oncology500 enrolled67 locationsNCT06377852
Recruiting
Phase 1Phase 2
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Metastatic Breast CancerBreast Cancer Stage IBreast Cancer Stage II+2 more
Forward Pharmaceuticals Co., Ltd.196 enrolled1 locationNCT07002177
Recruiting
Phase 2
Combined Immunotherapies in Metastatic ER+ Breast Cancer
Breast Cancer
Weill Medical College of Cornell University102 enrolled3 locationsNCT04563507
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 2
PLATFORM Study of Precision Medicine for Rare Tumors
Rare Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences770 enrolled1 locationNCT04423185
Recruiting
Phase 1
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
CancerSolid Tumor
Lebanese University50 enrolled2 locationsNCT06307249